Revision as of 23:03, 12 December 2012 edit Rod57 (talk \| contribs) Autopatrolled, Extended confirmed users, Pending changes reviewers 32,520 edits →‎VEGFR antagonists: Regorafenib was approved for colrectal cancer in Sept 2012. ← Previous edit		Revision as of 23:04, 12 December 2012 edit undo Rod57 (talk \| contribs) Autopatrolled, Extended confirmed users, Pending changes reviewers 32,520 edits m →‎VEGFR antagonists: o Next edit →
Line 73: ==VEGFR antagonists== Some VEGFR antagonists (inhibitors) (for example [[lenvatinib]], [[motesanib]]) are under investigation for treating various cancers. [[Pazopanib]] was approved for [[renal cell carcinoma]] in 2009. [[Regorafenib]] was approved for [[~~colrectal~~colorectal cancer]] in Sept 2012. ==References==

VEGF receptor: Difference between revisions